8-KRegulation FDExhibits & Filings

GE HealthCare Technologies Inc. 8-K Report, Regulation FD Disclosure (Jul 29, 2026)

Filed July 29, 2026For Securities:GEHC

Summary

GE HealthCare Technologies Inc. (GEHC) has filed an 8-K to disclose a strategic reorganization of its business segments, effective Q2 2026. The company has combined its Imaging and Advanced Visualization Solutions businesses into a new 'Advanced Imaging Solutions' (AIS) segment. This move is intended to enhance execution, accelerate innovation, and improve operational efficiencies. Following this change, GE HealthCare will now report under three distinct segments: AIS, Pharmaceutical Diagnostics (PDx), and Patient Care Solutions (PCS). This new structure aligns with how the Chief Operating Decision Maker assesses performance and allocates resources. The AIS segment will encompass a broad range of diagnostic, interventional, and digital imaging technologies. Key product lines within AIS include Computed Tomography (CT), Magnetic Resonance (MR), Molecular Imaging (MI), solutions for Enterprise Imaging, Women's Health products (X-ray and Ultrasound), and general X-ray systems. The segment also includes offerings for CardioVascular and Interventional Solutions, as well as Surgical Innovations, and Comprehensive Care Ultrasound. The recast historical financial information reflecting this new segment structure is provided as an exhibit to aid investor comparability.

Key Highlights

  • 1GE HealthCare has reorganized its business into three reportable segments: Advanced Imaging Solutions (AIS), Pharmaceutical Diagnostics (PDx), and Patient Care Solutions (PCS).
  • 2The new AIS segment combines the former Imaging and Advanced Visualization Solutions businesses to drive efficiency and innovation.
  • 3The AIS segment's offerings span diagnostic, interventional, and digital imaging technologies across various clinical specialties.
  • 4Key product lines within AIS include CT, MR, Molecular Imaging, Enterprise Imaging software, Women's Health solutions, and X-ray systems.
  • 5Procedural guidance and specialized ultrasound offerings are also integrated into the new AIS segment.
  • 6This segment restructuring aligns with the company's strategic leadership changes and aims to enhance operational focus.
  • 7Recast historical financial information has been provided to ensure investor comparability with the new segment structure.

Frequently Asked Questions

The primary purpose of this 8-K filing is to announce and provide recast unaudited historical financial information related to a strategic change in GE HealthCare's reportable segments. The company has combined its Imaging and Advanced Visualization Solutions businesses into a new 'Advanced Imaging Solutions' (AIS) segment, bringing the total number of reportable segments to three.

The creation of the AIS segment is a strategic decision aimed at enhancing execution, accelerating innovation, and creating efficiencies by consolidating related imaging and visualization technologies. This segment will house a comprehensive suite of diagnostic, interventional, and digital imaging products and solutions, offering a more integrated approach to serving customers across various clinical areas.

Following the reorganization, GE HealthCare will now report under three main segments: Advanced Imaging Solutions (AIS), Pharmaceutical Diagnostics (PDx), and Patient Care Solutions (PCS). This structure reflects how the company's Chief Operating Decision Maker reviews performance and allocates resources.

No, this segment restructuring does not impact previously reported financial statements for any period. The filing includes recast unaudited historical financial information solely to provide investors with comparable data under the new segment structure.